Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update
07:00am, Friday, 06'th Aug 2021
Positive interim results from Single Ascending Dose portion of Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 demonstrated degrader proof-of-mechanism
Data demonstrate Kymera's ability to degrade mutant and wild-type STAT3, a traditionally “undruggable” target, and the broad therapeutic potential for the treatment of peripheral T-cell lymphoma s
Kymera Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
09:45pm, Wednesday, 30'th Jun 2021
WATERTOWN, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m
Kymera Therapeutics Seeks To Raise Capital Via 4M Shares Equity Offering To Fund Oncology Franchises
08:56am, Tuesday, 29'th Jun 2021
Kymera Therapeutics Inc (NASDAQ: KYMR) commenced an underwritten public offering of 4 million shares of common stock. Underwriters can purchase up to an additional 600k shares.
Kymera Therapeutics Announces Proposed Public Offering of Common Stock
04:36pm, Monday, 28'th Jun 2021
WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m
KYMR Stock Price Increases Over 8% Pre-Market: Why It Happened
09:01am, Monday, 28'th Jun 2021
The stock price of Kymera Therapeutics Inc (NASDAQ: KYMR) increased over 8% pre-market. This is why it happened.
KT-474 has achieved and exceeded Phase 1 target degradation of 85% within the SAD portion of the Phase 1 trial dosed to date, with 90% median degradation at the 300 mg dose
Kymera Therapeutics Appoints Elaine Caughey, MBA, as Chief Business Officer
04:00pm, Monday, 21'st Jun 2021
WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m
Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity
11:20am, Monday, 21'st Jun 2021
Kymera Therapeutics Inc (NASDAQ: KYMR) has announced new preclinical data on its IRAKIMiD degrader KT-413's potential as both a monotherapy and in combination with other anticancer agents. The data
Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
04:00pm, Wednesday, 02'nd Jun 2021
WATERTOWN, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m
Kymera Therapeutics Honored by Boston Business Journal as a 2021 Best Places to Work Company
07:30am, Monday, 19'th Apr 2021
WATERTOWN, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small
KYMR Stock: 16.76% Increase Explanation
09:02pm, Wednesday, 14'th Apr 2021
The stock price of Kymera Therapeutics Inc (NASDAQ: KYMR) increased by 16.76%. This is why it happened.
KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1 Interferon pathways resulting in superior antitumor activity in MYD88-mutant DLBCL models
WATERTOWN, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small
Kymera Therapeutics Appoints Elena Ridloff, CFA, to Board of Directors
04:01pm, Tuesday, 16'th Mar 2021
WATERTOWN, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small
